Basic Information
NEOTIGASON CAPSULE 25 mg
CAPSULE
Regulatory Information
SIN08392P
October 16, 1995
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XD05BB02
Company Information
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Active Ingredients
Strength: 25 mg
Detailed Information
Contraindications
**Contraindications** Neotigason is highly teratogenic and must not be used by women who are pregnant. The same applies to women of childbearing potential unless strict contraception is practised 4 weeks before, during and for 3 years after treatment (see below). Women of childbearing potential must not receive blood from patients being treated with Neotigason. Donation of blood by a patient being treated with Neotigason is prohibited during and for 3 years after completion of treatment with Neotigason. Neotigason is contraindicated in patients with severely impaired liver or kidney function and in patients with chronic abnormally elevated blood lipid values. Since both Neotigason and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated. An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate. Consequently, the combination of methotrexate with Neotigason is also contraindicated. Concomitant administration of Neotigason and vitamin A or other retinoids is contraindicated due to the risk of hypervitaminosis A. Neotigason is contraindicated in cases of hypersensitivity to the preparation (acitretin or excipients) or to other retinoids.
Indication Information
**Indications** _Severe forms of psoriasis including_ - erythrodermic psoriasis - local or generalized pustular psoriasis _Severe disorders of keratinization, such as_ - congenital ichthyosis; - pityriasis rubra pilaris; - Darier’s disease; - other disorders of keratinization which may be resistant to other therapies.